



IFW

PATENT
Attorney Docket No. 056291-5181

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Sue Ann CARTLIDGE)	Confirmation No.: 2797
)	
Application No.: 10/507,164)	Group Art Unit: 1615
)	
Filed: September 9, 2004)	Examiner: Unassigned
)	
For: The Use of an Epitope of Vascular Endothelial)	
Growth Factor Receptor KDR/FLK-1)	

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

May 9, 2006

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants request that the Examiner consider this Supplemental Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Supplemental Information Disclosure Statement.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that the listed documents constitute "prior art" under United States law,

Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** -in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP



By: _____

Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

Date: May 9, 2006
Morgan Lewis & Bockius LLP
Customer No. 009629
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) May 9, 2006 PTO Form 1449				Attorney Docket No. 056291-5181		Application No. 10/507,164	
Applicants Sue Ann CARTLIDGE				PAGE 1 of 1			
Filing Date September 9, 2004				Group Art Unit 1615			

RECEIVED
 MAY 09 2006
 U.S. PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS							
Initial		Document No.	Name	Class	Sub-Class	Filing Date	

FOREIGN PATENT DOCUMENTS							
	Document No.	Date	Country	Class	Sub-Class	Translation	
1.	WO 0229090	April 11, 2002	WIPO			Yes	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)	
2.	Clauss M (2000) Molecular biology of the VEGF and the VEGF receptor family Semin Thromb Hemost. 26(5)561-569
3.	Cullinan-Bove K et al. (1993) Vascular endothelial growth factorvascular permeability factor expression in the rat uterus rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth Endocrinology 133 829-837
4.	Cunningham SA et al. (1997) Interactions of FLT-1 and KDR with phospholipase C gamma. Identification of the phosphotyrosine binding sites Biochem. Biophys. Res. Comm. Biochem. Biophys. Res. Comm. 240635-639
5.	Dougher M et al. (1999) Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization Oncogene 18(8)1619-1627
6.	Fan TP et al. (1995) Controlling the vasculature angiogenesis, anti-angiogenesis and vascular targeting of gene therapy Trends Pharmacol Sci. 16(2)57-66
7.	Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease Nature Medicine. 1(1)27-31
8.	Karkkainen MJ et al. (2000) Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis Oncogene 195598-5605
9.	Kendall RL et al. (1999) Vascular Endothelial Growth Factor Receptor KDR Tyrosine Kinase Activity Is Increased by Autophosphorylation of Two Activation Loop Tyrosine Residues J Biol Chem 274(10)6453-6460
10.	McMahon G (2002) VEGF receptor signaling in tumor angiogenesis Oncologist. 5 Suppl 13-10
11.	Ratcliffe KE et al. (2002) Sck is expressed in endothelial cells and participates in vascular endothelial growth factor-induced signaling Oncogene 21(41)6307-6316
12.	Senger DR et al. (1993) Vascular Permeability Factor (VPF, VEGF) in Tumor Biology Cancer Met Reviews 12303-324
13.	Terman BI et al. (1991) Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 61677-1683
14.	Terman BI et al. (1992) Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor Biochem Biophys Res Commun. 187(3)1579-1586
15.	Warner AJ et al. (2000) The Shc-related adaptor protein, Sck, forms a complex with the vascular-endothelial-growth-factor receptor KDR in transfected cells Biochem J. 347(Pt 2)501-509
16.	Zeng H (2001) Tyrosine Residues 951 and 1059 of Vascular Endothelial Growth Factor Receptor-2 (KDR) Are Essential for Vascular Permeability FactorVascular Endothelial Growth Factor-induced Endothelium Migration and Proliferation, Respectively J. Biol. Chem. 276(35)32714-32719

Examiner	Date Considered
----------	-----------------

Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.